Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7087122 | 0.90 | ABCB11 (0.78) | ABCB11CCR2 | |
| SCHEMBL7086626 | 0.87 | ABCB11 (0.66) | ABCB11CCR2 | |
| SCHEMBL6596985 | 0.86 | ABCB11 (0.78) | ABCB11CCR2 | |
| SCHEMBL7087363 | 0.86 | ABCB11 (0.52) | ABCB11CCR2 | |
| SCHEMBL7086723 | 0.81 | ABCB11 (0.77) | ABCB11CCR2 | |
| SCHEMBL7082850 | 0.81 | ABCB11 (1.00) | ABCB11CCR2 | |
| SCHEMBL7082975 | 0.80 | ABCB11 (0.74) | ABCB11CCR2 | |
| SCHEMBL7087035 | 0.79 | ABCB11 (0.67) | ABCB11CCR2 | |
| SCHEMBL7083010 | 0.79 | ABCB11 (0.72) | ABCB11CCR2 | |
| SCHEMBL7135340 | 0.79 | ABCB11 (0.60) | ABCB11CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | claimed |
| EP-1252142-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-10-30 | — | — | EP | claimed |
| WO-2001051466-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-07-19 | — | — | WO | claimed |
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144339-A1 | Indole derivatives as mcp-1 receptor antagonists | CCR2, CCR1, CCR5 | ABCB11 391/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.